Company News

Connect with us at BIO International Convention Digital Event 2021!

Updates for A166 (HER2 ADC) will be presented at 2022 ASCO Annual Meeting

Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.

Image-empty-state.png

May 29, 2022

KLUS Pharma is Attending BIO International Convention in San Diego!

KLUS Pharma will attend 2022 BIO International in San Diego from June 13-16.

Image-empty-state.png

May 15, 2022

KLUS Pharma is Attending BIO-Europe Spring 2022

KLUS Pharma will attend BIO-Europe Spring to be held virtually from March 28-31, 2022.

Image-empty-state.png

March 1, 2022

KLUS Pharma is Attending 40th Annual J.P. Morgan Health Care Conference

KLUS Pharma will attend the 40th Annual J.P. Morgan Health Care Conference to be held virtually from January 10-13, 2022

Image-empty-state.png

January 1, 2022

KLUS Pharma is Attending 2021 BioPharm America Digital Conference

KLUS Pharma will attend 2021 BioPharm America Digital Conference held from September 20-23.

Image-empty-state.png

September 10, 2021

Kelun-Biotech Will Present an Update on SKB264 at 2021 ESMO

Kelun-Biotech will present an oral update on SKB264 at 2021 ESMO Annual Meeting held from September 16-21.

Image-empty-state.png

September 10, 2021

KLUS Pharma is Attending BIO International Convention Digital Event

KLUS Pharma will attend BIO International Convention Digital 2021 from June 14-18.

Image-empty-state.png

May 20, 2021

Kelun-Biotech Will Present Updates for A166 at ASCO

Kelun-Biotech will attend and present at ASCO 2021 for A166, an anti-HER2 ADC.

Image-empty-state.png

May 20, 2021

Kelun-Biotech and Ellipses Pharma Announce a Licensing Agreement for A400

Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and UK company Ellipses Pharma Ltd. Announce a Licensing Agreement for Innovative Small Molecule Cancer Therapeutics

Image-empty-state.png

March 26, 2021

KLUS Pharma is Attending BIO-Europe Spring

KLUS Pharma will attend BIO-Europe Spring Digital Event held on March 22-25, 2021.

Image-empty-state.png

March 5, 2021

KLUS Pharma is Attending BIO Partnering at JPM

KLUS Pharma will attend BIO Partnering at JPM Digital Event held on January 11-15, 2021.

Image-empty-state.png

December 5, 2020

IND for KL-A289 is Approved in China

The IND for KL-A289, an anti-LAG-3 monoclonal antibody, was recently approved by the NMPA in China.

Image-empty-state.png

September 2, 2020